

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Ken Fujise et al.

Serial No.: 10/021,753

Filed: October 30, 2001

For: METHODS AND COMPOSITIONS  
RELATING TO FORTILIN, AN ANTI-  
APOPTOTIC MOLECULE, AND  
MODULATORS OF FORTILIN

Group Art Unit: 1635

Examiner: Jon E. Angell

Atty. Dkt. No.: UTSH:251US

Confirmation No.: 6306

**CERTIFICATE OF ELECTRONIC SUBMISSION**

DATE OF SUBMISSION: November 7, 2006

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. § 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be


construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/UTSH:251US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

  
Steven L. Highland  
Reg. No. 37, 642

 Gina M. Shishima  
Reg. No. 45,104  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: November 7, 2006

Form PTO-1449 (modified)		Atty. Docket No. UTSH:251US	Serial No. 10/021,753
List of Patents and Publications for Applicant's		Applicant Ken Fujise <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: October 30, 2001	Group: 1635
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 01/18046	03/15/01	WIPO	English
	B2	WO 94/12881	06/09/94	WIPO	English
	B3	WO 98/04291	02/05/98	WIPO	English

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Gachet <i>et al.</i> , "The growth-related translationally controlled protein p23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle," <i>Journal of Cell Science</i> , 112:1257-1271, 1999.
	C20	Sinha <i>et al.</i> , "Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis," <i>Electrophoresis</i> , 21: 3048-3057, 2000.

25689048.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)